ART Medical

Company Overview

Snapshot

Founded in September 2008 by Liron Elia, ART Medical operates with 51–200 employees. The company has raised $82.3M across six funding rounds from three investors. In July 2023, a new clinical study demonstrated unprecedented results for ART Medical's smART+ Platform, including significant reductions in ICU length of stay and ventilation days, alongside improved feeding efficacy.

Business overview

ART Medical develops an all-in-one nutrition management platform designed to detect and prevent feeding-related complications and optimize patient nutrition, thereby accelerating recovery. Its core technology, smART+, is a sensor-based feeding tube that identifies and prevents reflux events. The company aims to mitigate ICU-acquired complications such as aspiration pneumonia, ventilator-associated events, malnutrition, and acute kidney injury. ART Medical operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Digital Healthcare, serving healthcare providers in the United States and Israel.

Strategic signal

In March 2023, ART Medical announced a strategic partnership with Teva Israel to integrate its technology into critical care units. This collaboration signals a significant market validation and expansion for ART Medical, indicating a move towards broader adoption of its life-saving solutions within the healthcare industry and reinforcing its position as a key innovator in critical care technology.

Company Intelligence Q&A

What is ART Medical's primary mission?

ART Medical's mission is to modernize critical care and prevent ICU-acquired complications like aspiration pneumonia, ventilator-associated events, malnutrition, and acute kidney injury, ultimately aiming to save lives.

What is the smART+ platform?

smART+ is ART Medical's sensor-based feeding tube designed to detect and prevent reflux events, ensuring optimal patient nutrition and accelerating recovery.

When was ART Medical founded and by whom?

ART Medical was founded in September 2008 by Liron Elia.

What was a key finding from the clinical study in July 2023?

A clinical study in July 2023 showed that ART Medical's smART+ Platform led to a significant reduction in ICU length of stay, ventilation days, and improved feeding efficacy.

What strategic partnership did ART Medical announce in March 2023?

In March 2023, ART Medical announced a partnership with Teva Israel to introduce its technology into critical care units.